Synovial Sarcoma Market Insights, Emerging Drugs, and Market Report 2032
DelveInsight’s Synovial Sarcoma Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Synovial Sarcoma market share of the individual therapies, current and forecasted Synovial Sarcoma market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Synovial Sarcoma Overview
Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8–10% of all soft tissue sarcomas (STS). Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms but can appear in any part of the body. Being a high-grade tumor, it spreads to distant sites in about half of the cases. Synovial sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated.
Download Sample Report @ Synovial Sarcoma Market
Some of the key features of the Synovial Sarcoma Market Report
- DelveInsight’s assessment suggests that the United States accounts for the highest number of incident cases of synovial sarcoma (i.e., 576 cases in 2019) in comparison to the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
- The Synovial Sarcoma market size in 7MM was estimated at USD 59.43 Million in 2019
- Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. The hybrid transcription factor SS18:SSX alters SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling and global methylation patterns that may allow future therapeutic opportunities.
- Synovial Sarcoma companies such as Advenchen Laboratories, Adaptimmune Therapeutics, GlaxoSmithKline, and several others.
- Synovial Sarcoma therapies such as Pazopanib, Tazemetostat, ADP-A2M4, Anlotinib (AL3818), and several others
Synovial Sarcoma Causes
The exact underlying cause of synovial sarcoma is poorly understood. However, studies indicate that translocation between chromosome X and chromosome 18 appears to play a role in the development of synovial sarcoma. This translocation is specific to synovial sarcoma and is often used to diagnose the condition.
In the early stages of the condition, synovial sarcoma may cause no noticeable signs or symptoms but as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit the range of motion or cause numbness and/or pain if it presses on nearby nerves.
Current treatment of Synovial Sarcoma involves multimodal approach, incorporating surgery, chemotherapy, and radiotherapy. Currently, surgery remains the mainstay for treatment of synovial sarcoma. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. However, DelveInsight’s market forecast model is based entirely on pharmacological therapies and does not include any procedural or surgical methods.
As per the latest treatment paradigms, chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response. Doxorubicin and ifosfamide constitute the first-line approach generating a large segment of synovial sarcoma’s chemotherapeutic market.
Synovial Sarcoma Emerging Drugs Analysis
The landscape of Synovial Sarcoma market is speculated to change in the coming years owing to the launch of several upcoming therapies. A significant amount of research and developmental activities over the past several years have led to the gradual emergence of more effective and less toxic treatment modalities in Synovial Sarcoma (SS) patients. Although at present Pazopanib remains the only targeted drug approved for the treatment of soft tissue sarcomas in the advanced settings after failure of standard cytotoxic therapy, but the situation is will undergo a dynamic change during the forecast period. Advenchen Laboratories, Adaptimmune, and Epizyme are the top players that are actively working on development of therapies for Synovial Sarcoma.
Get an overview of the market @ Synovial Sarcoma Market Report
Table of Content
1. Key Insights
2. Executive Summary of Synovial Sarcoma
3. Competitive Intelligence Analysis for Synovial Sarcoma
4. Synovial Sarcoma: Market Overview at a Glance
5. Synovial Sarcoma: Disease Background and Overview
6. Patient Journey
7. Synovial Sarcoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Synovial Sarcoma Unmet Needs
10. Key Endpoints of Synovial Sarcoma Treatment
11. Synovial Sarcoma Marketed Products
12. Synovial Sarcoma Emerging Therapies
13. Synovial Sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Synovial Sarcoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Get in touch with our Business Expert @ Synovial Sarcoma Market Insights
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
